Table 2. Treatment outcomes regarding recurrences.
| Author | Median f/u (total) | Trastuzumab group | Control group | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median f/u | T1b (%) | Grade 3 (%) | HR− (%) | Recurrence/total | DR | CTx. (%) | HTx. (%) | Median f/u | T1b (%) | Grade 3 (%) | HR− (%) | Recurrence/total | DR | CTx. (%) | HTx. (%) | |||
| Rodrigues | 44 months | 40 months | 79.8 | 46.5 | 53.5 | 2/129 (1.6%) | 0/129 | ATC/taxane (42.6); ATC (28.7); taxane (28.7) | 45.7 | 49 months | 58.5 | 17 | 23.6 | 13/123 (10.6%) | 6/123 (4.9%) | 0 | 65.9 | |
| Tognela | 51 months | – | 73 | 80 | 47 | 1/30 (3.3%) | 0/30 | ATC/taxane [23]; ATC [7]; taxane [63] |
53 | – | 56 | 38 | 38 | 2/16 (12.5%) | 1/16 (6.3%) | ATC [6] | 44.0 | |
| Olszewski | 64 months | – | – | – | – | 1/111 (0.9%) | – | – | – | – | – | – | – | 8/94 (8.5%) | – | – | – | |
| Fehrenbacher | 5.8 years | – | – | – | – | 0/19 (0%) | 0/19 | CTx. (84.2) | – | – | – | – | – | 12/215 (5.6%) | 7/215 (3.3%) | CTx. (20.5) | – | |
| Mcarthur | 6.5 years | 3.0 years |
78 | 96† | 43 | 2/54 (3.7%) | 0/54 | ATC [15]; taxane [39]; ATC/taxane [43]; other CTx. [4] | 54 | 6.5 years | 49 | 52† | 42 | 9/45 (20.0%) | 1/45 (2.2%) | ATC [24]; taxane [2]; ATC/taxane [9]; other CTx. [7] | 53 | |
| Gori | 37 months | – | 76 | 52 | 33 | 3/204 (1.5%) | – | CTx. [75] | 63 | – | 49 | 38 | 66 | 8/99 (8.1%) | – | CTx. [7] | 60.6 | |
| Horio | 4.3 years | – | – | – | – | 1/5 (20.0%) | 0/5 | CTx. [100] | 20 | – | – | – | – | 3/37 (8.1%) | 1/37 (2.7%) | CTx. (35.1) | 24.3 | |
†, grade 2 and 3. f/u, follow-up; DR, distant recurrence; CTx., chemotherapy; ATC, anthracycline; HTx., hormone therapy; LVI, lymphovascular invasion; HR−, hormone receptor negative.